Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 0.90 |
| ▸ | PDE6C | P51160 | 2/20 | 0.90 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL146830 | 1.00 | PDE5A (0.90) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL147337 | 0.95 | PDE5A (1.00) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL18069561 | 0.92 | PDE5A (0.77) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL7959160 | 0.92 | PDE5A (0.77) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL5964550 | 0.88 | PDE5A (0.70) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL7965731 | 0.88 | PDE5A (0.84) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL25013469 | 0.87 | PDE5A (0.85) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL29357402 | 0.87 | PDE5A (0.85) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL7964961 | 0.87 | PDE5A (0.85) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL30199753 | 0.87 | PDE5A (0.85) | PDE5APDE6CHDAC1HDAC6HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12186322-B2 | Liquid oral formulations for tadalafil | LIQMEDS WORLDWIDE LIMITED (GB) | 2025-01-07 | — | — | US | disclosed |
| US-12186321-B2 | Liquid oral formulations for sildenafil | LIQMEDS WORLDWIDE LIMITED (GB) | 2025-01-07 | — | — | US | disclosed |
| US-20240299396-A1 | LIQUID ORAL FORMULATIONS FOR PDE V INHIBITORS | LIQMEDS WORLDWIDE LIMITED (GB) | 2024-09-12 | — | — | US | disclosed |
| US-20240245688-A1 | LIQUID ORAL FORMULATIONS FOR TADALAFIL | LIQMEDS WORLDWIDE LIMITED (GB) | 2024-07-25 | — | — | US | disclosed |
| US-20240245689-A1 | LIQUID ORAL FORMULATIONS FOR SILDENAFIL | LIQMEDS WORLDWIDE LIMITED (GB) | 2024-07-25 | — | — | US | disclosed |
| US-12005062-B2 | Liquid oral formulations for sildenafil | LIQMEDS WORLDWIDE LIMITED (GB) | 2024-06-11 | — | — | US | disclosed |
| US-11975006-B2 | Liquid oral formulations for tadalafil | LIQMEDS WORLDWIDE LIMITED (GB) | 2024-05-07 | — | — | US | disclosed |
| US-20230381187-A1 | LIQUID ORAL FORMULATIONS FOR SILDENAFIL | LIQMEDS WORLDWIDE LIMITED (GB) | 2023-11-30 | — | — | US | disclosed |
| US-11759468-B2 | Liquid oral formulations for sildenafil | LIQMEDS WORLDWIDE LIMITED (GB) | 2023-09-19 | — | — | US | disclosed |
| US-20230285398-A1 | LIQUID ORAL FORMULATIONS FOR TADALAFIL | LIQMEDS WORLDWIDE LIMITED (GB) | 2023-09-14 | — | — | US | disclosed |
| US-11666576-B2 | Liquid oral formulations for tadalafil | LIQMEDS WORLDWIDE LIMITED (GB) | 2023-06-06 | — | — | US | disclosed |
| US-20220409621-A1 | LIQUID ORAL FORMULATIONS FOR SILDENAFIL | LIQMEDS WORLDWIDE LIMITED (GB) | 2022-12-29 | — | — | US | disclosed |
| US-11464778-B2 | Liquid oral formulations for sildenafil | LIQMEDS WORLDWIDE LIMITED (GB) | 2022-10-11 | — | — | US | disclosed |
| US-20220296602-A1 | LIQUID ORAL FORMULATIONS FOR TADALAFIL | LIQMEDS WORLDWIDE LIMITED (GB) | 2022-09-22 | — | — | US | disclosed |
| US-11382917-B2 | Liquid oral formulations for tadalafil | LIQMEDS WORLDWIDE LIMITED (GB) | 2022-07-12 | — | — | US | disclosed |
| US-11337979-B2 | Liquid oral formulations for sildenafil | LIQMEDS WORLDWIDE LIMITED (GB) | 2022-05-24 | — | — | US | disclosed |